M. Hitt

Establishing combination PAC-1 and TRAIL regimens for treating ovarian cancer based on patient-specific pharmacokinetic profiles using in silico clinical trials

This paper uses in silico clinical trials to optimize combination PAC-1 and TRAIL therapy for ovarian cancer based on patient-specific pharmacokinetic profiles, identifying optimal treatment schedules and patient subgroups.

Breast tumor-associated metalloproteases restrict reovirus oncolysis by cleaving the σ1 cell-attachment protein, and can be overcome by mutation of σ1

This study shows that breast tumor-associated metalloproteases cleave reovirus σ1 protein, reducing infectivity, and demonstrates that a σ1 mutation can overcome this inactivation.